31 results about "Malignant effusion" patented technology

The invention discloses a method for utilizing a malignant pleural effusion for separately culturing primary cancer cells. The method comprises the steps of putting a pleural effusion sample into a sample collecting liquid, and centrifuging to remove a supernatant; adding a red blood cell lysis buffer for removing a red blood cell, adding a PBS buffer solution for washing the cells, and centrifuging to remove a supernatant; using a KL culture medium for resuspending a cell precipitate, inoculating in a culture flask, and culturing in a culture box. When the cells are proliferated to more than85 percent of abundance, the cells are washed through the PBS buffer solution, pancreatin-EDTA is digested, and a stop buffer neutralizes digestion reaction; the cells are centrifugally collected, areresuspended through the KL culture medium, and inoculated in the cell flask according to the proportion so as to be subcultured. The primary cancer cells of the pleural effusion obtained by separatedculture through the method provided by the invention can be applied to related research of physiology, pharmacy, new drug research and development and the like, exploration of pathogenesis of relateddiseases of a lung cancer, detection of drug sensitivity of different drugs, screening of anti-cancer drugs, new drug research and development, and establishment of a personalized treatment program aiming at a patient.

The invention relates to an isolated culture method for tumor-specific T cells and a product obtained through the method. The isolated culture method comprises the steps that firstly, peripheral bloodof a tumor patient is pretreated, mononuclear cells are separated from the peripheral blood, the mononuclear cells with positive PD-1 are separated out, finally, the mononuclear cells with positive PD-1 are amplified, and the tumor-specific T cells are obtained. An initial material involved by the isolated culture method for the tumor-specific T cells is the peripheral blood of the tumor patient,tumor tissue or malignant pleural effusion and ascites of the patient do not need to be used as the material, the material is more conveniently collected, blood sampling can be conveniently conductedon almost all tumor patients, and no large wounds are caused; the finally-obtained T cells are high in tumor specificity and comprise T cells with positive CD4 and T cells with positive CD8; the method is simple in operation process and short in required time.

The invention provides a medicine composite for treating malignant pleural effusion. The medicine composite is prepared with, by weight, 2-18 parts of American ginseng, 4-30 parts of pseudo-ginseng, 2-18 parts of pepperweed seeds, 3-21 parts of pyrrosia lingua, 2-8 parts of seeds of zanthoxylom bungeanum maxim, 10-50 parts of cynanchum paniculatum, 5-25 parts of snake gourd fruits, 10-50 parts of raw radix astragalis, 2-18 parts of rhizoma alismatis, 3-21 parts of rhizoma atractylodis macrocephalae and 2-12 parts of Chinese dates. All ingredients cooperate with one another, the medicine composite is placed in water for dissolution before drinking and is effective in warming the Yang, smoothing the Qi, communicating the Yang and the Qi, excreting the dampness and tonifying the spleen, and all medicine cooperate to achieve that the Yang is warmed and the effusion is relieved. Clinical tests prove that the medicine composite is capable of effectively treating the malignant pleural effusion.

Method for gentle separation of viable sporadic cells from body fluids such as blood, from malignant effusions, bronchoalveolar lavage fluid, peritoneal lavage fluid and amniotic fluid, based on a filter membrane which is in an intimate contact with an absorbent material. Using the present method it is possible to isolate for example circulating and disseminated tumor cells, endometrial cells and circulating trophoblast cells, allowing subsequent detection, quantification, characterization and especially culturing of said cells. An apparatus for carrying out the method is further disclosed.

The invention discloses a cancer therapeutic medicine capable of killing medicine-resistant tumor cells and tumor stem cells in chemicotherapy and an application thereof. The medicine is characterized by comprising the following components: the liquid medicine in every 100 milliliters contains 2-10ml of absolute ethyl alcohol, 40-50mg of cis-platinum complexes and 90-98ml of sterile water. The medicine is mainly used for local injection of tumors or intravesical therapy of chest, abdomen, pericardial cavity malignant effusion or aerosol inhalation therapy of lung tumors, and is suitable for the therapy of various solid tumors such as lung cancer, liver cancer, pancreatic cancer, ovarian cancer, cervical cancer, mammary cancer, retroperitoneal tumor or retroperitoneal lymph node metastasis, cardia cancer, gastrointestinal malignant cancer, soft tissue sarcoma, glioma and head and neck neoplasm and the medicine-resistant or medicine-sensitive tumor therapy with chest, abdomen, pericardial cavity malignant effusion.

The invention discloses lentinan nano-selenium, a preparation method and application of the lentinan nano-selenium in treatment of malignant pleural effusion. The preparation method comprises the following steps: (1) respectively dissolving lentinan, sodium selenite and ascorbic acid in water to obtain corresponding solutions; (2) uniformly mixing the lentinan solution with a sodium selenite solution and an ascorbic acid solution respectively to obtain a lentinan / sodium selenite mixed solution and a lentinan / ascorbic acid mixed solution; and (3) dropwise adding the lentinan / sodium selenite mixed solution into the lentinan / ascorbic acid mixed solution, and conducting stirring for reaction to obtain the lentinan nano-selenium. Through comparison, it is found that the lentinan nano-selenium prepared through the method can be taken by immune cells in malignant pleural effusion (MPE), MPE in a cold state is converted into functional hot state, the immune function of a patient is improved, and therefore the lentinan nano-selenium can be used for treating tumors and malignant pleural effusion.

The invention belongs to the technical field of malignant pleural effusion detection methods, and specifically relates to a method for identifying the malignant pleural effusion by using CD14+CD163+cells. The method comprises the following steps of extracting mononuclear cells, labeling antibodies, and performing immunophenotyping analysis by using a flow cytometry. Compared with the prior art, the method provided by the invention has the advantages that the method is simple and convenient and rapid, the sensitivity is high, the specificity is high, meanwhile, the interference of man-made subjective factors is reduced by using the method, the method is objective, judgment and identification can be made for the potential malignant pleural effusion patient as soon as possible, and convenience is provided for the subsequent in-time intervention treatment.

The invention discloses a micromolecular marker for the diagnosis of malignant pleural effusion and an application thereof, wherein the micromolecular marker comprises the following 11 compounds of: valine, lactate, alanine salt, acetacetate, creatinine, trimethyl-amine oxide, betaine, alpha- and beta-glucose, leucine and isoleucine. In allusion to the components of pleural effusion of cancer patients and the content variation of the components, the micromolecular marker, which has strong specificity, high sensitivity and high appraisal result accuracy and is used for the diagnosis of malignant pleural effusion, is selected by the combination of the nuclear magnetic resonance technology and the stepwise discriminant function analysis method; in particular, lactate, acetacetate, trimethyl-amine oxide, betaine and alpha-glucose can sensitively, accurately and efficiently identify benign and malignant pleural effusion, which is of great significance for accurately diagnosing malignant pleural effusion such as lung cancer at an early stage, striving for much more treatment time for patients and raising the clinic treatment effect.

The invention relates to a tumor treatment method for patients with terminal malignant tumor lung metastasis with malignant pleural effusion. The method includes the steps: draining and collecting pleural effusion from cancerous hydrothorax appearing in a patient with lung metastasis, centrifuging and enriching, then separating out metastatic pleural effusion mononuclear cells (PEMC), adjusting the concentration of 5*10<5> / ml in pores of a 24-pore plate, placing in an incubator, amplifying the PEMC with combined application of peripheral blood mononuclear cells (PBMC) in healthy adults after irradiation with IL-2, and taking the PBMC after irradiation as trophocytes to stimulate the amplification and cytotoxicity tests of the PEMC. The invention also provides a use of the PEMC prepared bythe method in preparation of drugs for treating terminal malignant tumor lung metastasis with malignant pleural effusion. The advantages show that provided is a PEMC amplification method with higher efficiency and relatively convenient technology, the amplification efficiency reaches 1000 times, and high cytotoxicity killing effect is achieved.

The invention discloses an application of IGKC, C9, AHSG and KNG1 in distinguishing tuberculous pleural effusion and malignant pleural effusion. A system for detecting the IGKC, C9, AHSG and KNG1 contents includes a system for detecting the IGKC content, a system for detecting the C9 content, a system for detecting the AHSG content and a system for detecting the KNG1 content by an enzyme-linked immunosorbent assay or a liquid chromatography-electrospray ionization tandem mass spectrometry. By using the system for detecting the IGKC, C9, AHSG and KNG1 contents, the accuracy in distinguishing patients with the tuberculous pleural effusion and patients with the malignant pleural effusion is 97.5%; the sensitivity in screening patients with the malignant pleural effusion is 100%, and the specificity is 96%; the sensitivity in screening patients with the tuberculous pleural effusion is 96%, and the specificity is 100%.

The invention discloses a cell brush used for pleural brushing inspection and a using method thereof, relates to the technical field of medical instruments, and solves the problem that no special cellbrush used for pleural brushing inspection exists in the prior art, bronchoscope cell brushes are adopted in some literature reports, the cell brushes are too long and do not match with the exists pleural biopsy syringe, the cell brushes are difficult to sent out and take back, and artificial pneumothorax easily appears. The key points of the technical scheme are that: the cell brush comprises asleeve and a needle core inserted into the sleeve and further comprises a sealing tube and a cell brush body movably connected to the sealing tube, the sealing tube is sealingly connected to the sleeve; one end of the cell brush body is provided with a cell brush head, and the other end is provided with a cell brush handle; and the end of the sealing tube is fixedly connected to a clamping body near the cell brush handle, and the cell brush body is movably connected to the clamping body. The structure has the effects of making the cell brush simple to sent out and take back, facilitating pleural brushing inspection, increasing the number of tumor cells in the pleural effusion and improving the diagnostic positive rate of the malignant effusion.

The invention discloses a target MYO9B related to malignant pleural effusion and application of the target MYO9B. The invention further discloses any of the following 1)-5) application: 1) application of a substance inhibiting the activity of MYO9B protein in preparing a product for treating or assisting treatment of malignant pleural effusion; 2) application of the substance inhibiting the activity of MYO9B protein in preparing a product for lowering or reducing the amount of pleural effusion in patients with malignant pleural effusion; 3) application of a substance that inhibits or silences MYO9B gene expression in preparing the product for treating or assisting treatment of malignant pleural effusion; 4) application of the substance that inhibits or silences MYO9B gene expression in preparing the product for lowering or reducing the amount of pleural effusion in patients with malignant pleural effusion; 5) application of MYO9B protein and related signaling pathways thereof as targets in developing or designing the product of treating or assisting treatment of malignant pleural effusion.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine dressing for treating malignant pleural effusion. After the malignant pleural effusion is treated by conventional methods such as systemic chemotherapy, local treatment in the thoracic cavity, thermal therapy and surgical treatment, the recurrence rate in a short period is relatively high. In order to solve the problems, the traditional Chinese medicine dressing for treating malignant pleural effusion, provided by the invention, is prepared from astragalus membranaceus, semen pharbitidis, polyporus umbellatus, semen coicis, radix stephaniae tetrandrae, rhizoma alismatis, herba lycopi, zanthoxylum bungeanum maxim, borneol, garden balsam stem, poria cocos, cassia twig, ground beetle, areca-nut, nightshade, pericarpium arecae, euphorbia kansui and leech. The traditional Chinese medicine dressing is obtained through optimization based on an existing prescription, and has an outstanding treatment effect on malignant pleural effusion and can effectively control the increase of pleural effusion.

The invention discloses a traditional Chinese medicine composition for treating malignant pleural effusion, which belongs to the field of traditional Chinese medicines. The traditional Chinese medicine composition is composed of the following traditional Chinese medicines in parts by weight: 4-12 parts of Rehmannia glutinosa, 1-3 parts of Angelica sinensis, 1-3 parts of fried yam, 1-3 parts of Cornus officinalis, 1-3 parts of Poria cocos, 1-3 parts of Polyporus cocos 1-3 servings of Alisma, 1-3 servings of Tinglizi, 1-3 servings of Haijinsha, 1 serving of Chicken Negonia, and 1 serving of Amomum. The traditional Chinese medicine composition of the invention has the effects of nourishing the liver and kidney, diuresis and eliminating dampness, and can effectively slow down the formation of malignant pleural effusion, thereby improving the quality of life and prolonging the survival time of patients.

The present disclosure provides a novel pharmaceutical composition for treating a malignant pleural effusion (MPE), including a benzenesulfonamide derivative and a pharmaceutically acceptable excipient. The present disclosure further provides a method for treating MPE by using the pharmaceutical composition.

The invention relates to a cavity circulating heat perfusion device, which includes a casing, an electromagnetic induction heating device and a controller. The electromagnetic induction heating device includes a tray and an electromagnetic induction coil. The tray is used to carry a heating tank. The magnetic induction coil is energized to heat the heating tank to indirectly heat the liquid medicine in the liquid storage chamber. The data acquisition unit is used to collect the temperature values ​​of the liquid medicine in the heating tank, the liquid outlet pipeline and the liquid return pipeline and transmit them to the main control unit. The main control unit controls the power control unit according to the temperature value of the liquid medicine to control the heating power of the electromagnetic induction coil. When the temperature of the liquid medicine reaches a predetermined temperature, the temperature is kept constant. Since the medicinal liquid is heated to a predetermined temperature before being passed into the bladder for treatment, it can fully exert the thermal killing mechanism after being passed into the bladder, and can kill the metastatic cancer cells widely planted on the serosa and eliminate the risk of malignant effusion. Focus, to achieve the purpose of effective treatment of cancerous effusion, effectively improve the treatment effect.

The invention relates to application of an immunoregulation composition in treatment of malignant effusion. The composition has an immunoregulation effect. The invention in particular relates to application of the composition in preparation of medicines for relieving and treating malignant effusion, wherein the composition contains polyriboside-polyribocytosine (PIC). The composition can further contain at least one stabilizer and calcium ion, and an anticancer agent or other pharmaceutically acceptable carriers.

The invention discloses a medicine composition for treating malignant pleural effusion and a preparation method of the medicine composition. The medicine composition is prepared from the following raw materials by weight: 15-25 parts of rabdosia rubescens, 10-20 parts of curcuma wenyujin, 5-15 parts of brucea javanica, 5-15 parts of radix sophorae flavescentis, 8-12 parts of arisaema erubescens, 8-12 parts of poria cocos, 7-13 parts of fructus aurantii, 5-15 parts of glossy privet fruit, 12-18 parts of herba epimedii, 7-13 parts of konjak, 12-18 parts of rice sprout, 15-25 parts of oldenlandia, 15-25 parts of sculellaria barbata, 5-13 parts of paris polyphylla, 7-13 parts of centipede, and 2-10 parts of scabrous elephantfoot herb; the various materials are extracted with water or ethyl alcohol to prepare the medicine composition, the chemotherapy is conducted with the medicine composition at the same time, the excellent synergistic interaction effects are achieved, no effect of inhibiting the bone marrow is produced, the synthesis of RNA and the protein is also not affected, the medicine composition has a remarkable effect of inhibiting the adhesion of a vascular endothelial cell of a neoplastic cell nuclei, directly stimulates pleura to lead to adhesion and fibrosis, has the effects of strongly astringing and inhibiting the secretion of the pleura, is an effective medicine for treating the malignant pleural effusion, and has a huge clinical application prospect.

The invention relates to a method for preparing high-killing-activity TIL cells in batches from malignant pleuroperitoneal fluid. The method comprises the steps that (338.6+ / -134.2)*10<8>(n=25) TIL cells can be obtained when culture is performed for 21-28 d, the cells are amplified by 179.6+ / -24.2 times, wherein, CD3+cells account for 98.61%+ / -3.22%, CD3+CD8+cells account for 74.56%+ / -5.19%, CD3+CD4+cells account for 27.42%+ / -6.35%, CD3+CD56+cells account for 51.88%+ / -7.49%, and CD4+CD25+FoxP3+ Tregs cells only account for 3.27%+ / -1.75%. The killing activity for tumor cells can reach 66.54%+ / -5.18% (according to a 4h51Cr release method, the effect / target ratio is equal to 40:1).

The invention provides a malignant pleural effusion tumor cell separation device and method. The separation device comprises a containing tank, a vibration filter sieve, a drainage funnel and a filter cup, wherein the vibration filter sieve, the drainage funnel and the filter cup are all located in the containing tank; the vibration filter sieve is provided with a first microfiltration membrane; and the filter cup is provided with a second microfiltration membrane. The filter cup is arranged in the vibration filter sieve, so that the second microfiltration membrane is aligned with the first microfiltration membrane. The micropore diameter of the first microfiltration membrane and the micropore diameter of the second microfiltration membrane are set, so that thymic tumor cells can remain on the second microfiltration membrane when pleural effusion containing cells to be removed sequentially passes through the first microfiltration membrane and the second microfiltration membrane. The separation method comprises a use method of the separation device. The separation device and method have the advantages that the tumor cells can be quickly and efficiently separated and enriched from the pleural effusion, a high-purity and high-concentration sample can be provided for detection and identification of the downstream pleural tumor cells, the pathogen detection time is shortened, and the pathogen detection accuracy is improved.

The invention provides a medicine composite for treating malignant pleural effusion. The medicine composite is prepared with, by weight, 2-18 parts of American ginseng, 4-30 parts of pseudo-ginseng, 2-18 parts of pepperweed seeds, 3-21 parts of pyrrosia lingua, 2-8 parts of seeds of zanthoxylom bungeanum maxim, 10-50 parts of cynanchum paniculatum, 5-25 parts of snake gourd fruits, 10-50 parts of raw radix astragalis, 2-18 parts of rhizoma alismatis, 3-21 parts of rhizoma atractylodis macrocephalae and 2-12 parts of Chinese dates. All ingredients cooperate with one another, the medicine composite is placed in water for dissolution before drinking and is effective in warming the Yang, smoothing the Qi, communicating the Yang and the Qi, excreting the dampness and tonifying the spleen, and all medicine cooperate to achieve that the Yang is warmed and the effusion is relieved. Clinical tests prove that the medicine composite is capable of effectively treating the malignant pleural effusion.

The invention discloses a traditional Chinese medicine composition for treating malignant pleural effusion, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicinecomposition is prepared from the following traditional Chinese medicines of, in parts by weight, 4-12 parts of prepared rehmannia root, 1-3 parts of angelica sinensis, 1-3 parts of fried Chinese yam,1-3 parts of dogwood, 1-3 parts of poria cocos, 1-3 parts of polyporus umbellatus, 1-3 parts of rhizoma alismatis, 1-3 parts of semen lepidii, 1-3 parts of spora lygodii, 1 part of endothelium corneumgigeriae galli and 1 part of fructus amomi. The traditional Chinese medicine composition has the effects of tonifying liver and kidney, inducing diuresis and resolving dampness, and can be used for effectively slowing down the generation of malignant pleural effusion, so that the living quality of patients is improved, and the survival time is prolonged.

The invention discloses a malignant pleural effusion detection method based on a multi-dimensional purification and enrichment technology. The malignant pleural effusion detection method comprises the following steps that: abdominal tumor pleural effusion of a patient is acquired; a pleural effusion drainage device is used for draining the pleural effusion of the patient through a puncture drainage method, and then the pleural effusion is submitted for inspection; the pleural effusion is analyzed, pathological characteristics are obtained; the to-be-detected pleural effusion is detected by using a flow cytometer, the existence of multinuclear cells is judged, the to-be-detected pleural effusion is centrifuged by using a density gradient centrifugation method to obtain pleural effusion cast-off cells, the pathological type of a tumor is judged on the basis of cytology immunohistochemistry, finally DNA is extracted from the pleural effusion cast-off cells, and molecular gene detection is carried out; a targeted drug and clinical treatment are determined; and sensitive drugs and targeted drugs of tumor cells are determined according to the obtained pathological type and gene mutation data of the tumor cells. The malignant pleural effusion detection method based on the multi-dimensional purification and enrichment technology has the advantages of low cost and easiness in operation, and just cause little harm to patients.

The invention provides an analysis method for a volatile organic compound in pleural effusion. The method comprises the steps of headspace solid phase microextraction, cold trap focusing and gas chromatographic and mass spectrometry combination. The method with the combination of the cold trap focusing and gas chromatographic and mass spectrometry combination on the basis of the headspace solid phase microextraction technology can rapidly and accurately analyze the volatile organic compound in the pleural effusion. According to the analysis method, extraction, enrichment and sample introduction are integrated into headspace solid phase microextraction, operation is easy and convenient, no complex pretreatment process is needed, complex matrix interference of biological samples is eliminated, and component information distortion in samples is not caused; due to the cold trap focusing technology, the high-volatility organic compound in the pleural effusion is condensed and secondarily analyzed at low temperature and effectively separated on the proper chromatographic condition. According to the analysis method, the volatile organic compound in the pleural effusion can be rapidly detected, quanlitative and semi-quantitative analysis is performed, and the analysis method is of great importance in distinguishing benign and malignant pleural effusion and even screening lung cancer markers by applying difference analysis.

The invention belongs to the field of diagnosis and treatment of malignant pleural effusion related diseases, and relates to a cytokine model for prognosis evaluation of a malignant pleural effusion patient and application. According to the cell factor model, the cell factor score CRPI is equal to n1 * x1 + n2 * x2... n32 * x32; wherein n1-n32 are coefficients shown in the table 1 in sequence, and x1-x32 are relative expression quantities of the cell factors in the table 1 in sequence. The prognosis evaluation device comprises a detection unit and an analysis unit, the detection unit is used for detecting the relative expression quantity of cell factors in a sample; the analysis unit takes the relative expression quantity of cell factors as an input variable, inputs the input variable into the prediction model, and analyzes the prognosis state of the malignant pleural effusion patient; the equation of the prediction model is the above formula. The cell factor model for prognosis evaluation of the malignant pleural effusion patient or the prognosis evaluation device is applied to preparation of a malignant pleural effusion prognosis diagnosis reagent. According to the method, the prediction model is constructed by taking the relative expression quantity of the cell factors as an input variable, and the benign and malignant prognosis of the malignant pleural effusion patient can be accurately predicted.